Historically, the primary focus of cancer research has been molecular and clinical studies of
a few essential pathways and genes. Recent years have seen the rapid accumulation of …

Combination of anti-cancer drugs is broadly seen as way to overcome the often-limited
efficacy of single agents. The design and testing of combinations are however very …

Precision oncology has made significant advances, mainly by targeting actionable mutations
in cancer driver genes. Aiming to expand treatment opportunities, recent studies have begun …

Kinase inhibitors suppress the growth of oncogene driven cancer but also enforce the
selection of treatment resistant cells that are thought to promote tumor relapse in patients …

While amino acid restriction remains an attractive strategy for cancer therapy, metabolic
adaptations limit its effectiveness. Here we demonstrate a role of translational …

Simple Summary Around 5–10% of advanced melanoma patients progress early on anti-
BRAF targeted therapy and 20–30% respond only with the stabilization of the disease …

Background Precision oncology is gradually advancing into mainstream clinical practice,
demonstrating significant survival benefits. However, eligibility and response rates remain …

Malignant mesothelioma is an aggressive cancer with limited treatment options and poor
prognosis. A better understanding of mesothelioma genomics and transcriptomics could …

Background Synthetic lethality (SL) denotes a genetic interaction between two genes whose
co-inactivation is detrimental to cells. Because more than 25 years have passed since SL …

Drug resistance is a principal limiting factor in cancer treatment. CTR-DB, the Cancer
Treatment Response gene signature DataBase, is the first data resource for clinical …